Paras Healthcare Completes USD153 Million IPO
In this article (4)
Paras Healthcare has completed a USD153 million initial public offering in India, advised by AZB & Partners, Hogan Lovells Cadwalader, and S&R Associates.
AZB & Partners acted for the issuer alongside promoter selling shareholder Dharminder Kumar Nagar. The firm deployed a team featuring senior partner Agnik Bhattacharyya, partner Sweta Ananthanarayanan, and senior associate Tanaiy Tewari.
S&R Associates acted for the book-running lead managers, while Hogan Lovells Cadwalader served as international counsel to an underwriting group comprising JM Financial, BofA Securities India, and Nuvama Wealth Management. Hogan Lovells Cadwalader capital markets partner Biswajit Chatterjee led the firm’s advisory team on the issue in late 2026.
The Listing and Anchor Backers
Paras Healthcare is a leading clinical specialty-led hospital platform providing tertiary and quaternary healthcare services under the Paras Health brand.
International underwriters managed the global book-building process, supported by domestic investment banks. The underwriting syndicate comprised JM Financial, BofA Securities India, and Nuvama Wealth Management. AZB & Partners advised the issuer and selling shareholder Dharminder Kumar Nagar, while S&R Associates and Hogan Lovells Cadwalader represented the book-running lead managers and international underwriters.
Operator Strategy and Regional Expansion
Capital deployment in India’s regional hospital sector has shifted heavily toward mid-tier metros where consumer purchasing power has increased faster than specialized bed capacity. Operators in secondary cities encounter lower real estate acquisition costs and less direct competition from established national networks.
Private hospital chains face rising clinical staff recruitment expenses and longer payback periods when installing advanced diagnostic machinery. For regional healthcare operators, converting bed count into sustainable operational cash flow requires maintaining high average revenue per occupied bed alongside steady patient footfall from domestic health insurance schemes.
Institutional Demand for Indian Healthcare
Sovereign wealth funds and global asset managers have consistently funnelled capital into specialized hospital platforms across Asia. The participation of Abu Dhabi Investment Authority and BlackRock in the anchor allocation shows institutional appetite for consumer healthcare assets with regional scale.
Institutional backers prioritize multi-specialty providers capable of building regional referral clusters rather than standalone facilities. By bundling pharmacy operations, outpatient consulting, and diagnostics into physical facilities, network operators insulate operating margins against regulatory price caps on essential medical treatments.
Preceding Deal Flow and Pipeline
The transaction follows a steady run of Indian primary market issues across industrial and healthcare segments through late 2026. Domestic capital markets have accommodated substantial liquidity exits for private equity investors and company founders seeking public market valuations.
Paras Healthcare must now deploy the fresh equity proceeds into planned bed additions and specialty medical technology across its core regional network, with quarterly patient volume metrics and occupancy ratios serving as the immediate operational benchmarks.